Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 31 to 45 of 56 results for lenalidomide

  1. NICE noted that the cost effectiveness of lenalidomide compared with standard care for people with low- or intermediate-1-risk MDS associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate, was sensitive to whether the patient access scheme would be realised in clinical practice. The Committee agreed that it would be critical to generate evidence to support the following: - The proportion of people who become eligible for the patient access scheme, that is, that they remain on treatment beyond 26 cycles. - The benefit of lenalidomide after 26 cycles, that is the associated overall survival and health related quality of life for those who remain on treatment beyond 26 cycles.

    TA322/1 Question NICE noted that the cost effectiveness of lenalidomide compared with standard care for people with low- or...

    Research recommendation
    Published
    9 June 2015

  2. Lenalidomide for untreated follicular lymphoma ID1245

    Discontinued [GID-TA10308]

    Technology appraisal guidance
    Discontinued

  3. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued [GID-TA10254]

    Technology appraisal guidance
    Discontinued

  4. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued [GID-TAG511]

    Technology appraisal guidance
    Discontinued

  5. Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]

    Discontinued [GID-TA10480]

    Technology appraisal guidance
    Discontinued

  6. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413

    Awaiting development [GID-TA11488] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.

    Technology appraisal guidance
    Published
    7 June 2023
    View recommendations

    Sections for TA894

  8. Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

    Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.

    Technology appraisal guidance
    Published
    27 March 2024
    View recommendations

    Sections for TA959

  9. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]

    In development [GID-TA10905] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Plitidepsin with dexamethasone for treating multiple myeloma after 3 previous therapies including bortezomib and lenalidomide [ID1081]

    Discontinued [GID-TA10171]

    Technology appraisal guidance
    Discontinued

  11. Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]

    In development [GID-TA10926] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Past appeals and decisions

    transthyretin amyloid cardiomyopathy 4-5 March 2021 TBC Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large...

  13. Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA939)

    Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults.

    Technology appraisal guidance
    Published
    13 December 2023
    View recommendations

    Sections for TA939

  14. Allogeneic stem cell transplantation:- What is the effectiveness of combined autologous–allogeneic stem cell transplantation compared with autologous stem cell transplantation, plus consolidation and maintenance treatment in chemosensitive patients at first response or first relapse?

    transplantation. These studies were performed before thalidomide, bortezomib and lenalidomide were used as myeloma treatments.These...

    Research recommendation
    Published
    5 April 2016

  15. Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for marginal zone lymphoma after anti-CD20-based treatment in adults.

    Technology appraisal guidance
    Published
    4 September 2024
    View recommendations

    Sections for TA1001